College to corporate: notes from the RBMI Bareilly dialogue.

On 25 February 2026 I spent an afternoon at the AV Room of RBMI Group of Institutions in Bareilly, in front of a room of pharmacy and management students who had signed up for a session billed as Pharmacy College-to-Corporate Dialogue. The format was a conversation, not a lecture. I was on stage in dialogue with Mr Akhlesh Mathur, Director of ICT UK Ltd, with the student cohort coming in on the floor. The remit, set by the college, was simple: skip the corporate slide deck, take questions, and tell the students what the industry actually looks like once they leave the campus gate.

What follows is a written record of the three questions the students kept circling, the answers I gave them, and the reasoning underneath. It is published here because the questions were not specific to that room. They are the same questions I have been asked at three other industry-academia sessions over the past two years, and they are worth a longer answer than an hour in an AV room allows.

The setting: an AV room, a room full of careers in the making

RBMI runs a mixed cohort: B Pharm and D Pharm students alongside management students in pharmaceutical marketing and healthcare administration tracks. The combination is useful, because the career conversation in pharmacy is not one conversation. It is at least three. The student who plans to register as a pharmacist and dispense medicines has a different decision tree from the student who wants to write a Common Technical Document dossier for a manufacturer, who in turn is in a different place from the student who wants to manage a Gulf-tender response desk.

The session was organised under the umbrella of RBMI's Institution's Innovation Council (a Ministry of Education initiative) and ran in partnership with ICT UK Ltd. The Dialogue format suited the topic. Students came with prepared questions, then opened the floor for live ones. Mr Mathur, who has run industry-academia interfaces in the UK and India for over a decade, framed many of the opening lines; my role was to answer them from the export-house side. The energy in the room was practical rather than aspirational. Nobody asked about salaries in the abstract. Several asked, very directly, about specific roles and how to qualify for them.

How should a student actually choose a career goal in pharma?

The honest answer, which I gave first, is that the question is the wrong shape. A pharmacy degree does not point at one career goal. It opens at least eight distinct lanes:

• Retail and hospital pharmacy. The classical pharmacist role. Direct patient interface, dispensing, clinical counselling. Largest single employer of pharmacy graduates in India.
• Manufacturing QA and QC. Inside a WHO-GMP or EU-GMP plant, on the production floor or in the analytical lab. The technical core of the industry.
• Regulatory affairs. Preparing dossiers, filing with CDSCO and overseas regulators, managing variations and renewals. The lane where pharmacology meets paperwork meets cross-border trade. Where I sit, professionally.
• Medical writing. Authoring summaries, periodic safety updates, study reports. Useful for graduates who write well and like reading clinical literature.
• Clinical research. Clinical research associate, site coordinator, pharmacovigilance officer. Trial-side work for sponsors and CROs.
• Pharmaceutical sales and marketing. Field-force, brand management, market access. The volume employer of pharmacy graduates who want a customer-facing trajectory.
• Pharmaceutical export and international business development. What M Care does. Indian-side sourcing, dossier preparation, destination-country registration and tender response, end-to-end supply.
• Academic and research. Masters and doctoral programmes, faculty appointments, formulation R&D inside industry research labs.

Telling a student to pick a career in pharma is like telling a medical graduate to pick a speciality. The decision is not the degree, it is the lane. My advice to the room was to think about three things before locking in the lane:

1. The work itself, not the brand. Spend two days shadowing in each lane that interests you before you commit. The fantasy version of a job rarely survives a 9 am Tuesday at the desk. Find out what the actual Tuesday looks like before you sign for it.
2. The geography of the employer. Retail pharmacy is everywhere. Regulatory affairs is concentrated in Mumbai, Hyderabad, Ahmedabad and Bengaluru, with a smaller cluster in Delhi NCR. Pharmaceutical export is similarly concentrated. If a student cannot or will not relocate, the lane choice narrows fast. Be honest about that constraint up front.
3. The pace of skill compounding. Some lanes compound skill quickly (regulatory affairs, formulation R&D, clinical research), where every project teaches you a transferable framework. Others compound slowly (retail dispensing). Neither is wrong. Pick the pace that matches the kind of career arc you want.

I closed that section with the line I keep coming back to in these sessions: the question is not what your career goal should be, the question is which lane of pharma you want to spend a decade getting good at. The decade compounds whichever lane you pick. Pick deliberately.

How pharma export works, end to end

Several students at RBMI were in the management track and wanted the export answer in operational detail. The simple version, in plain language, runs in seven steps.

1. The destination-country authorisation. Before the first carton leaves India, the product must be registered with the destination-country drug regulator (the marketing authorisation), or it must be moving under a named-patient permit for unlicensed imports. Registration is filed using a Common Technical Document (CTD) dossier, in five modules, harmonised across most regulators.
2. The purchase order. An importer in the destination country, licensed by their regulator, raises a purchase order specifying product, strength, pack, quantity, batch requirement and destination warehouse.
3. The Indian-side documentation pack. The exporter pulls the standing documentation set: WHO-GMP certificate of the manufacturing site, CDSCO Certificate of Pharmaceutical Product (CoPP), batch Certificate of Analysis from the manufacturer's QC lab, Free Sale Certificate, Certificate of Origin from an accredited Indian chamber of commerce or FIEO, commercial invoice, packing list, and a pack insert in the destination-market language.
4. Freight booking. Air for time-critical and small-volume lanes, sea for larger consignments and cost-sensitive corridors. Cold-chain validated shipping for biologicals, vaccines and certain hormones. Continuous temperature loggers travel with every 2 to 8 degree Celsius consignment.
5. Indian customs clearance. Drug Controller NoC where required, shipping bill, and electronic submission through ICEGATE. The exporter or their licensed CHA (Customs House Agent) drives this end.
6. Destination customs and regulator inspection. The consignment lands at the destination port (Jeddah, Dubai, Lagos, Mombasa, London Gatwick or Heathrow, depending on lane). Customs checks the paperwork; the destination drug regulator may inspect physically, review documentation only, or release on reliance pathway. Cold-chain integrity is checked on arrival for biologicals.
7. Release to the importer. Once cleared, the consignment is released to the importer's warehouse and from there to the hospital pharmacy, retail wholesaler or central medical store that originated the demand.

End-to-end, a routine shipment runs three to six weeks. A first-time shipment into a new market, with a new dossier in flight, runs three to twelve months because the upstream registration step dominates the timeline.

The students who asked about export careers also asked about salaries. My answer there: a first-year regulatory affairs analyst in Mumbai earns less than a first-year IT analyst in Bengaluru, but the compounding curve is steeper. Five years in, a CTD-fluent regulatory professional with a track record on three or four overseas registrations is one of the most portable employees in the Indian pharmaceutical industry. Ten years in, the same person can move into international business development, lead a regulatory function, or set up their own consulting practice. The arc rewards patience.

The documents that travel with every shipment

This was the question that produced the most note-taking in the room. Worth listing the documentation chain in plain order, because no textbook I have seen explains it cleanly.

1. WHO-GMP certificate of the manufacturing site. Issued in India by the State Licensing Authority, referenced by CDSCO. Certifies that the factory complies with WHO Good Manufacturing Practice. Long-lived, reissued periodically.
2. Common Technical Document (CTD) dossier. Five modules: administrative, summaries, chemistry / manufacturing / controls, non-clinical, clinical. The technical case for the product, filed with the destination regulator.
3. Destination-country Marketing Authorisation or named-patient permit. The legal authorisation to import and sell.
4. Purchase Order. From the licensed importer to the exporter, with quantity, pack and destination.
5. Certificate of Pharmaceutical Product (CoPP). Issued by CDSCO in WHO format, product-and-site specific, dated. Typically valid two years.
6. Free Sale Certificate (FSC). A shorter cousin of the CoPP, confirming the product is freely sold or freely exportable from India.
7. Certificate of Analysis (CoA). Batch-specific, issued by the manufacturer's QC lab. Lists assay, related substances, dissolution and other release tests.
8. Certificate of Origin. Issued by an accredited Indian chamber of commerce or FIEO. Confirms the country of manufacture for customs and tariff purposes.
9. Commercial invoice and packing list. Standard cross-border trade documents, but with pharmaceutical-specific details: batch number, expiry, pack composition.
10. Destination-country import permit. Issued by the destination drug regulator (MOHAP in UAE, SFDA in Saudi Arabia, NAFDAC in Nigeria, KEMSA framework approval in Kenya). Specific to the consignment, not the product.
11. Pack inserts in the destination-market language. Arabic for the GCC, French for francophone West Africa, the destination official language elsewhere.
12. For cold-chain consignments. Continuous temperature logger record, pre-shipment thermal mapping report of the qualified shipper, on-arrival CAPA protocol document.

For the students aiming at regulatory affairs, this list is the foundation. Build deep familiarity with each document, learn what a destination authority looks for when it picks each one up, and you have the skill set that hires.

Questions from the floor

A few of the live questions, and the short version of the answers:

Q. Do I need a Masters degree to work in pharmaceutical export?

A. No, not at the entry level. A B Pharm with regulatory affairs internship experience can start as a Regulatory Affairs Analyst or Documentation Coordinator. A Masters helps later, particularly for technical lanes (formulation, analytical method development). For documentation and international business development roles, demonstrated competence matters more than degree depth.

Q. How do I find an internship at a pharmaceutical exporter as a student?

A. Three routes. First, your college placement cell. Most B Pharm colleges have at least one industry connect, and increasingly the management institutes do too. Second, direct outreach to the regulatory affairs lead at exporters whose product lanes interest you. Third, LinkedIn outreach to working regulatory professionals with a specific, polite, single-paragraph request. Generic mass-messaging gets ignored. Specific outreach with a real question gets read.

Q. Is regulatory affairs a stable career given the rise of AI?

A. Regulatory affairs is one of the safer pharmaceutical careers under AI pressure for two reasons. First, the work is high-stakes interpretation of regulator guidance and clinical evidence, which still rewards human judgement. Second, every destination regulator is its own evolving system with its own queries, its own pricing committees and its own inspection regimes. AI tools accelerate document drafting, but the responsibility for the regulatory filing sits with a named human professional. That accountability does not transfer.

A closing thought, and an open door

The closing point I made to the RBMI room is the closing point of this post. Pharmacy as a discipline is in a moment where Indian manufacturing is the global back-up source for at least a dozen therapeutic categories, the regulatory frameworks across the Gulf, Africa, and parts of South-East Asia have become more standardised, and the export desks that file the dossiers and ship the consignments are hiring. There is room for graduates who care about the work. The question is which lane each student picks, and how deliberately they commit to the decade of compounding that follows.

Thank you to the faculty and students of RBMI Group of Institutions, the Institution's Innovation Council team, and Mr Akhlesh Mathur of ICT UK Ltd for the questions and the engagement. If a student or faculty member at another institute is reading this and is interested in arranging a similar session, the contact route is below.

FAQ

What career options does a B Pharm graduate have beyond retail and hospital pharmacy?

At least eight: retail and hospital pharmacy, manufacturing QA and QC, regulatory affairs, medical writing, clinical research, pharmaceutical sales and marketing, pharmaceutical export and international business development, and the academic and research lane. Each has its own skill set, employer geography and earnings trajectory.

How does pharma export actually work in seven steps?

1. Destination-country marketing authorisation or named-patient permit. 2. Importer purchase order. 3. Indian-side documentation pack (WHO-GMP, CoPP, CoA, FSC, CoO, invoice, packing list, pack insert). 4. Freight booking with cold-chain where required. 5. Indian customs clearance through ICEGATE. 6. Destination customs and regulator inspection. 7. Release to the importer's warehouse. End-to-end runs three to six weeks for routine repeat shipments.

Which destination regulator should an aspiring pharma export professional study first?

Pick the corridor that interests you most and learn its regulator deeply. MHRA for UK, SFDA for Saudi Arabia, MOHAP for UAE, NAFDAC for Nigeria, PPB for Kenya, SAHPRA for South Africa, FDA Ghana for West Africa entry. CDSCO is the Indian-side regulator everyone needs to know. The Gulf and African corridors are where Indian manufacturing has the strongest market share and where hiring is most active.

How long does CTD dossier preparation take for a generic product?

Roughly twelve to eighteen months from kick-off to filing, for a first-time generic dossier built on existing manufacturing data. Modules 2 to 5 can be partly reused across markets. Module 1 is destination-specific and rebuilt for each filing. Bioequivalence study lead times sit on top of the dossier timeline where applicable.